Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated glomerular filtration rate of \<90 ml/min.~2. Male and female patients on diet and exercise regimen who are pre-treated with any antidiabetic therapy and are on the maximum tolerated dose which has been unchanged for 12 weeks prior to randomisation.~3. HbA1c greater than or equal to 7.0% and less than or equal to 10.0% .~4. Aged 18 years or above.~5. Body Mass Index less than or equal to 45 kg/m2~Exclusion criteria:~1. Uncontrolled hyperglycaemia defined as \>13.3 mmol/L after an overnight fast during placebo run-in.~2. Impaired renal function, defined as an estimated glomerular filtration rate \<15 ml/min.~3. Renal impairment requiring any form of chronic dialysis.~4. Requiring acute dialysis within three months prior to informed consent.~5. Renal transplant recipient.~6. Myocardial infarction, stroke or Transient Ischemic Attack within three months prior to informed consent.~7. Indication of liver disease.~8. Bariatric surgery within the past two years.~9. Medical history of cancer.~10. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell.~11. Contraindications to pre-existing background antidiabetic therapy.~12. Treatment with anti-obesity drugs.~13. Current treatment with systemic steroids or change in dosage of thyroid hormones within six weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes.~14. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and are not practising an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 tablets once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).